ascopubs.org

Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.

Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC). S1507: Phase II study of docetaxel and trametinib ...
Medscape

Reader Responds to "The Epidemic of Chronic Kidney Disease"

Thank you for participating in Dr. Craig Langman's editorial on the epidemic of chronic kidney disease (CKD). [1] We recognize the importance of early detection of CKD and also want to encourage ...
The American Journal of Managed Care

Updated MARIPOSA Data Highlight Clinical Impact of Upfront Dual Inhibition in EGFR+ NSCLC

The MARIPOSA trial demonstrates that amivantamab plus lazertinib significantly reduces resistance and extends survival in EGFR-mutated NSCLC compared to osimertinib. Dual inhibition of EGFR and MET by ...
The American Journal of Managed Care

PALOMA-2 Reinforces Efficacy of SubQ Amivantamab in EGFR-Mutated NSCLC: Sun Lim Min, MD, PhD

Subcutaneous amivantamab plus chemotherapy offers an equally effective treatment for EGFR exon 20 insertion non–small cell lung cancer (NSCLC), mirroring PAPILLON results of the intravenous ...